Report: Ex-Merck staffer working on insider-trading plea deal

Zachary Zwerko, the former Merck ($MRK) analyst caught up in an SEC investigation of insider trading, is reportedly working on a plea deal with prosecutors, according to Reuters. Zwerko and an old buddy allegedly worked up the scheme ahead of Merck's $3.9 billion buyout of Idenix last year. The SEC says he also passed on insider info regarding Ardea and ViroPharma. The SEC says the two made at least $722,000 from the scheme, setting up Zwerko for a charge that could have put him behind bars for 5 years. Story

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.